Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 10 New Entrants companies in Ribociclib
by Most Patent Filing In 3 Years in the world in 2021

The Ribociclib top 10 is Discovery PatSnap’ annual ranking of the top 10 Most Patent Filing In 3 Years Ribociclib New Entrants in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2021, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Ontario, Canada
Patent: 4
2
California, United States
Patent: 4
3
Andhra Pradesh, India
Oncology,Medicine,Health care,
...[+2]
Patent: 3
4
Graduate degree,Academic Training,The Internet,
...[+2]
Patent: 3
5
Telangana, India
Patent: 2
6
Oklahoma, United States
Patent: 2
7
Military science,Materials science,Academic achievement,
...[+2]
Patent: 2
8
Tel Aviv, Israel
Gastrointestinal agent,Immunotherapy,Clinical trial,
...[+2]
Patent: 2
9
Patent: 1
10
Olaris, Inc.
Massachusetts, United States
Substance abuse,Health care,Biotechnology,
...[+2]
Patent: 1
Page generation time: Jul 07 2025